BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30487137)

  • 1. A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
    Kossenkov AV; Qureshi R; Dawany NB; Wickramasinghe J; Liu Q; Majumdar RS; Chang C; Widura S; Kumar T; Horng WH; Konnisto E; Criner G; Tsay JJ; Pass H; Yendamuri S; Vachani A; Bauer T; Nam B; Rom WN; Showe MK; Showe LC
    Cancer Res; 2019 Jan; 79(1):263-273. PubMed ID: 30487137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
    Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J
    BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test.
    Liang W; Chen Z; Li C; Liu J; Tao J; Liu X; Zhao D; Yin W; Chen H; Cheng C; Yu F; Zhang C; Liu L; Tian H; Cai K; Liu X; Wang Z; Xu N; Dong Q; Chen L; Yang Y; Zhi X; Li H; Tu X; Cai X; Jiang Z; Ji H; Mo L; Wang J; Fan JB; He J
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33793424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computer-aided diagnosis of lung cancer: the effect of training data sets on classification accuracy of lung nodules.
    Gong J; Liu JY; Sun XW; Zheng B; Nie SD
    Phys Med Biol; 2018 Feb; 63(3):035036. PubMed ID: 29311420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules.
    Lin Y; Leng Q; Jiang Z; Guarnera MA; Zhou Y; Chen X; Wang H; Zhou W; Cai L; Fang H; Li J; Jin H; Wang L; Yi S; Lu W; Evers D; Fowle CB; Su Y; Jiang F
    Int J Cancer; 2017 Sep; 141(6):1240-1248. PubMed ID: 28580707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
    Li X; Zhang Q; Jin X; Cao L
    World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
    Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
    J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules.
    Szpechcinski A; Rudzinski P; Kupis W; Langfort R; Orlowski T; Chorostowska-Wynimko J
    Cancer Lett; 2016 May; 374(2):202-7. PubMed ID: 26854716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a multiprotein plasma classifier to identify benign lung nodules.
    Vachani A; Pass HI; Rom WN; Midthun DE; Edell ES; Laviolette M; Li XJ; Fong PY; Hunsucker SW; Hayward C; Mazzone PJ; Madtes DK; Miller YE; Walker MG; Shi J; Kearney P; Fang KC; Massion PP
    J Thorac Oncol; 2015 Apr; 10(4):629-37. PubMed ID: 25590604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules.
    Liu QX; Zhou D; Han TC; Lu X; Hou B; Li MY; Yang GX; Li QY; Pei ZH; Hong YY; Zhang YX; Chen WZ; Zheng H; He J; Dai JG
    Adv Sci (Weinh); 2021 Jul; 8(13):2100104. PubMed ID: 34258160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients.
    Schotten LM; Darwiche K; Seweryn M; Yildiz V; Kneuertz PJ; Eberhardt WEE; Eisenmann S; Welter S; Sisson BE; Pietrzak M; Wiesweg M; Ploenes T; Hager T; He K; Freitag L; Aigner C; Taube C; Oezkan F
    Eur J Cancer; 2021 Apr; 147():142-150. PubMed ID: 33662689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of peripheral blood rare cell EGFR gene amplification detection in the evaluation of benign and malignant pulmonary nodules].
    Li H; Liu XQ; Yan LJ; Liu Y; Zhang JQ; Xiao YN; Li SQ
    Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1584-1589. PubMed ID: 38742345
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules.
    Vachani A; Hammoud Z; Springmeyer S; Cohen N; Nguyen D; Williamson C; Starnes S; Hunsucker S; Law S; Li XJ; Porter A; Kearney P
    Lung; 2015 Dec; 193(6):1023-7. PubMed ID: 26376647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.
    Silvestri GA; Tanner NT; Kearney P; Vachani A; Massion PP; Porter A; Springmeyer SC; Fang KC; Midthun D; Mazzone PJ;
    Chest; 2018 Sep; 154(3):491-500. PubMed ID: 29496499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer.
    Ajona D; Remirez A; Sainz C; Bertolo C; Gonzalez A; Varo N; Lozano MD; Zulueta JJ; Mesa-Guzman M; C Martin A; Perez-Palacios R; Perez-Gracia JL; Massion PP; Montuenga LM; Pio R
    Transl Res; 2021 Jul; 233():77-91. PubMed ID: 33618009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of malignancy of pulmonary nodules at CT scans: Effect of computer-aided diagnosis on diagnostic performance of radiologists.
    Liu J; Zhao L; Han X; Ji H; Liu L; He W
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):216-221. PubMed ID: 32757455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules.
    Seder CW; Kubasiak JC; Pithadia R; Basu S; Fhied C; Tarhoni I; Davila E; Alnajjar H; Chmielewski GW; Warren WH; Liptay MJ; Borgia JA
    Ann Thorac Surg; 2015 Aug; 100(2):429-36. PubMed ID: 26138771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.
    Hanas JS; Peyton MD; Lerner MR; Lightfoot SA; Deb SJ; Hanas RJ; Vu NT; Kupiec TC; Stowell DE; Brackett DJ; Dubinett SM; Hocker JR
    Cancer Invest; 2014 May; 32(4):136-43. PubMed ID: 24579933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-derived Autoantibodies Identify Malignant Pulmonary Nodules.
    Lastwika KJ; Kargl J; Zhang Y; Zhu X; Lo E; Shelley D; Ladd JJ; Wu W; Kinahan P; Pipavath SNJ; Randolph TW; Shipley M; Lampe PD; Houghton AM
    Am J Respir Crit Care Med; 2019 May; 199(10):1257-1266. PubMed ID: 30422669
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.